HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell, President and CEO, is scheduled to present a business overview and update at the Barclays Global Healthcare Conference on Tuesday, March 15 at 3:20pm ET in Miami, FL.
